Antiviral Activity of Selective Estrogen Receptor Modulators against Severe Fever with Thrombocytopenia Syndrome Virus In Vitro and In Vivo
Viruses · 2024
DOI: 10.3390/v16081332 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Xintong Yan und 21 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China. Hauptthemen laut MEDLINE: Antiviral Agents, Phlebovirus, Selective Estrogen Receptor Modulators, Severe Fever with Thrombocytopenia Syndrome. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hainan Provincial Natural Science Foundation of China, National Natural Science Foundation of China, National Science and Technology Major Projects for "Major New Drugs Innovation and Development", China.
Abstract (Originalsprache)
Severe fever with thrombocytopenia syndrome virus (SFTSV), also known as the Dabie Banda virus, is an emerging tick-borne Bunyavirus that causes severe fever with thrombocytopenia syndrome (SFTS). Currently, symptomatic treatment and antiviral therapy with ribavirin and favipiravir are used in clinical management. However, their therapeutical efficacy is hardly satisfactory in patients with high viral load. In this study, we explored the antiviral effects of selective estrogen receptor modulators (SERMs) on SFTSV infection and the antiviral mechanisms of a representative SERM, bazedoxifene acetate (BZA). Our data show that SERMs potently inhibited SFTSV-induced cytopathic effect (CPE), the proliferation of infectious viral particles, and viral RNA replication and that BZA effectively protected mice from lethal viral challenge. The mode of action analysis reveals that BZA exerts antiviral effects during the post-entry stage of SFTSV infection. The transcriptome analysis reveals that GRASLND and CYP1A1 were upregulated, while TMEM45B and TXNIP were downregulated. Our findings suggest that SERMs have the potential to be used in the treatment of SFTSV infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China.
- Song Li's Academician Workstation, School of Pharmaceutical Sciences, Hainan University, Yazhou Bay, Sanya 572000, China.
- National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
ORCID-Profile: Wu Zhong
Förderung
- Hainan Provincial Natural Science Foundation of China
- National Natural Science Foundation of China
- National Science and Technology Major Projects for "Major New Drugs Innovation and Development", China
- National Science and Technology Major Projects for “Major New Drugs Innovation and Development”, China
Zitieren
APA
Yan, X., Luo, C., Yang, J., Wang, Z., Shao, Y., Wang, P., Yang, S., Li, Y., Dai, Q., Li, W., Yang, X., Tao, H., Ren, S., Li, Z., Guo, X., Li, S., Zhu, W., Luo, Y., Li, J., …, & Zhong, W. (2024). Antiviral Activity of Selective Estrogen Receptor Modulators against Severe Fever with Thrombocytopenia Syndrome Virus In Vitro and In Vivo. Viruses. https://doi.org/10.3390/v16081332
Vancouver
Yan X, Luo C, Yang J, Wang Z, Shao Y, Wang P, et al. Antiviral Activity of Selective Estrogen Receptor Modulators against Severe Fever with Thrombocytopenia Syndrome Virus In Vitro and In Vivo. Viruses. 2024. doi:10.3390/v16081332
BibTeX
@article{Yan2024,
author = {Yan, Xintong and Luo, Chongda and Yang, Jingjing and Wang, Zhuang and Shao, Yunfeng and Wang, Ping and Yang, Shaokang and Li, Yuexiang and Dai, Qingsong and Li, Wei and Yang, Xiaotong and Tao, Huimin and Ren, Sichen and Li, Zhenyang and Guo, Xiaojia and Li, Siqi and Zhu, Weiyan and Luo, Yan and Li, Jiazheng and Li, Song and Cao, Ruiyuan and Zhong, Wu},
title = {Antiviral Activity of Selective Estrogen Receptor Modulators against Severe Fever with Thrombocytopenia Syndrome Virus In Vitro and In Vivo},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16081332}
}
EUVIMED